NA
TAK icon

NewEdge Advisors’s Takeda Pharmaceutical TAK Stock Holding History

NewEdge Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.27K Sell
328
-90
-22% -$1.49K ﹤0.01% 3709
2026
Q1 		$7.75K Buy
418
+35
+9% +$614 ﹤0.01% 3463
2025
Q4 		$5.96K Buy
383
+2
+0.5% +$29 ﹤0.01% 3630
2025
Q3 		$5.58K Sell
381
-15
-4% -$223 ﹤0.01% 3499
2025
Q2 		$6.13K Buy
396
+16
+4% +$236 ﹤0.01% 3356
2025
Q1 		$5.66K Sell
380
-25
-6% -$350 ﹤0.01% 3268
2024
Q4 		$5.37K Buy
405
+1
+0.2% +$14 ﹤0.01% 3222
2024
Q3 		$5.75K Sell
404
-12
-3% -$170 ﹤0.01% 3124
2024
Q2 		$5.38K Sell
416
-18
-4% -$238 ﹤0.01% 3075
2024
Q1 		$6.03K Sell
434
-92
-17% -$1.34K ﹤0.01% 3071
2023
Q4 		$7.51K Sell
526
-38,294
-99% -$543K ﹤0.01% 2973
2023
Q3 		$601K Sell
38,820
-334
-0.9% -$5.17K 0.01% 1086
2023
Q2 		$615K Buy
39,154
+38,794
+10,776% +$636K 0.01% 1082
2023
Q1 		$5.93K Sell
360
-5,092
-93% -$81.1K ﹤0.01% 2724
2022
Q4 		$79.4K Buy
+5,452
New +$76.2K ﹤0.01% 1530

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

NewEdge Advisors's TAK Position: Q2 2026 in Review

NewEdge Advisors reduced its Takeda Pharmaceutical (TAK) stake by 22% in Q2 2026, selling an estimated $1.49K and leaving 328 shares worth $5.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

NewEdge Advisors first reported a position in TAK in Q4 2022 and has held it in 15 quarters since. The position peaked at $615K in Q2 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • NewEdge Advisors held 328 shares of Takeda Pharmaceutical worth $5.27K as of Q2 2026.
  • NewEdge Advisors sold 90 Takeda Pharmaceutical shares in Q2 2026, an estimated $1.49K.
  • Takeda Pharmaceutical made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3709 holding.
  • NewEdge Advisors first reported a position in Takeda Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's Takeda Pharmaceutical position peaked at $615K in Q2 2023.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.